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Abstract: Polymersomes are nanosized vesicles formed from amphiphilic block copolymers, 
and have been identified as potential drug delivery vehicles to the inner ear. The aim of this study 
was to provide targeting to specific cells within the inner ear by functionalizing the polymersome 
surface with Tet1 peptide sequence. Tet1 peptide specifically binds to the trisialoganglioside 
clostridial toxin receptor on neurons and was expected to target the polymersomes toward the 
cochlear nerve. The Tet1 functionalized PEG-b-PCL polymersomes were administered using 
routine drug delivery routes: transtympanic injection and cochleostomy. Delivery via cochleo-
stomy of Tet1 functionalized polymersomes resulted in cochlear nerve targeting; in contrast 
this was not seen after transtympanic injection.
Keywords: nanoparticles, peptide, round window membrane, nerve fibers, spiral ganglion 
cell, drug delivery
Introduction
Targeted drug delivery aims to enhance the biological availability of a chosen 
therapeutic agent while reducing adverse effects. The ability to target drugs to the spiral 
ganglion cells (SGCs) and cochlear nerve (CN) would create an advanced therapeutic 
strategy for the treatment of sensorineural hearing loss. Composed of US Food and 
Drug Administration (FDA)-approved medical materials, poly(ε-caprolactone)-
block-poly(ethylene glycol) (PEG-b-PCL) polymersomes (PMs) are efficiently taken 
up by the SGCs and spiral ganglion Schwann cells. This occurs without overt toxicity 
in vitro spiral ganglion cultures indicating that this type of nanoparticle holds promise 
for drug delivery to treat sensorineural hearing loss.1 Targetability of PMs to the neural 
element of the cochlea was achieved through ligand mediated multivalent binding to 
tyrosine kinase receptors and to p75 neurotrophin receptors.2 However, no in vivo 
studies on the targetability of functionalized PMs were reported and there is a risk 
that targeting tyrosine kinase receptors and p75 neurotrophin receptors may result in 
altered cell signalling, which in turn may affect the neural activity and viability of 
the SGCs.
An alternative approach to targeting SGCs and their processes might be achieved by 
using the Tet1 peptide (sequence H-L-N-I-L-S-T-L-W-K-Y-R), which was identified 
by phage display and showed a strong affinity to differentiated PC12 cells, primary 
motor neurons, and dorsal root ganglion cells. Tet1 peptide binds to the trisialogan-
glioside clostridial toxin (GT1b) receptors,3 which are also expressed in the cochlea.4,5 
Any disruption in the neural activity and viability of SGCs might be avoided because 
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GT1b is not involved in SGC cell signalling. Modification of 
nanoparticles with the Tet1 peptide has resulted in improved 
targeted gene delivery to neurons both in vitro and in vivo.6,7 
We hypothesized that SGCs or CN targeted drug delivery 
could be achieved by using PEG-b-PCL PMs functionalized 
with the Tet1 peptide.
In our previous study, unlabelled PMs that were delivered 
onto the round window membrane (RWM) did not appear 
in SGCs and spiral ganglion satellite cells.8 In the present 
study, PMs were functionalized with the Tet1 peptide. The 
targetability was evaluated using two therapeutic approaches 
in which the PMs were delivered via either transtympanic 
injection or cochleostomy. The inner ear distribution of Tet1 
functionalized PMS (Tet1-PMS) was then assayed using 
confocal microscopy. Two different control samples of PMs, 
unlabelled PMs and PMs functionalized with a scrambled 
Tet1 sequence (ScrTet1), were used in this investigation.
Materials and methods
Materials
Anhydrous N,N-dimethylformamide (DMF), 4-nitrophenyl 
iodoacetate, and dialysis tubing with a 12–14 kDa cutoff 
and 6.3 mm diameter were purchased from Sigma-Aldrich 
(Gillingham, UK). Poly(ethylene glycol)-block-poly 
(ε-caprolactone) methyl ether, PEG average Mn ∼ 5800, 
PCL average Mn ∼ 19,000, (NH2-PEG5.8K-b-PCL19K), 
and (NH2-PEG5K-b-PCL5K) were supplied by Polymer 
Source Inc, (Dorval, Canada). 1,1′-dioctadecyl-3,3,3′3′-
tetramethylindocarbocyanine perchlorate (DiI) was supplied 
by Invitrogen (Paisley, UK). Peptide sequences were 
synthesized by Activotec (Cambridge, UK). Phosphate-
buffered saline (PBS) solution was made using PBS tablets 
(Oxoid, Basingstoke, UK) and H2O (purified using a Milli-Q 
Ultrapure Water Purification System [resistance of 18.2 
MΩcm at 25°C], Livingston, Cambridge, UK). Dynamic light 
scattering was performed on a Zetasizer Nano Z (Malvern 
Instruments Ltd, Malvern, UK).
Methods
Preparation of peptide functionalized polymer
NH2-PEG5.8K-b-PCL19K (60 mg) was dissolved in DMF 
(2 mL). 4-nitrophenyl-iodoacetate (10 mg) was added, and 
the reaction mixture stirred for 4 hours. Diethyl ether (50 mL) 
was added and the solution left overnight. The resulting 
precipitate was filtered and washed with diethyl ether to give 
iodoacetate-PEG5.8K-b-PCL19K functionalized polymer 
(45 mg, 75% yield). A total of 12 mg of the solid was dissolved   
into DMF (1 mL) to give a pale yellow solution that turned 
clear when cysteine   terminated peptide (1 mg) was added. The 
reaction mixture was stirred overnight, concentrated in vacuo, 
and used crude in PM preparation. The peptide sequences 
used were Tet1 (NH2-HLNILSTLWKYRC-COOH) and a 
ScrTet1   (NH2-LHNYTWLSLRKIC-COOH).
PM preparation
The carboxy cyanine dye DiI was dissolved in DMF at a 
concentration of 0.1 mg/mL. Tet1-PEG5.8K-b-PCL19K 
(6.0 mg) was added to the DiI/DMF solution (0.4 mL), and this 
was placed in an ultrasonic bath for 10 minutes to aid dissolution. 
The polymer solution was then added dropwise (∼1 drop every 
8 seconds) to rapidly stirred PBS (1.60 mL). The sample was 
then dialyzed against PBS (400 mL), and the buffer solution 
was replaced four times over the course of 48 hours, after which 
the sample was removed from the dialysis tubing. Control 
PMs with the scrambled ScrTet1 peptide (ScrTet1-PMs) and 
unlabelled PMs were made in an identical fashion using ScrTet1-
PEG5.8K-b-PCL19K and iodoacetate-PEG5.8K-b-PCL19K 
respectively   (Figure 1A). Analysis by dynamic light scattering 
showed the typical hydrodynamic diameter of the Tet1-PMs to 
be 105.0 ± 20.0 nm. Both the ScrTet1-PMs and unlabelled PMs 
had hydrodynamic diameters similar to the Tet1-PMs. The zeta 
potential measurements for the Tet1-PMs and ScrTet1-PMs were 
negative, with typical measurements for the Tet1/ScrTet1-PMs 
and unlabelled PMs being -0.764 and -0.578 mV , respectively. 
Before use in in vivo experiments, the PMs were sterile-filtered 
through a 0.2 µm cellulose acetate syringe filter.
Animals
Twenty-seven 5-month-old male SD rats with normal 
Pryer’s reflexes and weighing 350–450 g (supplied by the 
Experimental Animal Unit, University of  Tampere, FL) were 
used in this study. All rats were treated in accordance with the 
directives of the regional ethics committee of the   University 
of Tampere. All experimental procedures were performed 
under general anesthesia after intraperitoneal injection of 
a mixture of 0.8 mg/kg of medetomidine hydrochloride 
(Domitor, Orion, Espoo, Finland) and 80 mg/kg of ketamine 
hydrochloride (Ketalar; Pfizer, Helsinki, Finland).
The animals were assigned to two groups: in group 1, 
Tet1-PMs, ScrTet1-PMs, and unlabelled PMs were delivered 
by transtympanic injection bilaterally; in group 2, Tet1-
PMs, ScrTet1-PMs, and unlabelled PMs were delivered by 
cochleostomy unilaterally. Three days after administration 
of the PMs was begun, the animals were sacrificed and their 
cochleae were harvested. The cochleae were processed to 
either whole mounts or cryosectioning.
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Administration of PMs to the inner ear
Protocols for transtympanic injection and cochleostomy of 
PMs have previously been reported.8 Briefly, for transtym-
panic injection, 40 µL of each PM type was injected into the 
middle ear cavity; for cochleostomy, an osmotic pump filled 
with 100 µL of PMs (the PMs were diluted 1:1 with artificial 
perilymph) was connected to the scala tympani (ST) (via a hole 
in the bony labyrinth that was made with a 0.5 mm diameter 
burr) by a polyethylene tube prefilled with the same solution 
(Figure 1B). The analysis was carried out blind, the PMs were 
coded prior to administration, and evaluation of the tissue by 
confocal microscopy was completed before decoding.
During the procedure, the animals’ eyes were protected 
with Terramycin eye cream (Pfizer). Atipamezole hydrochlo-
ride (2 mg/kg) was injected intraperitoneally immediately 
after the operation to accelerate the animals’ recovery from 
anesthesia. Saline (2 mL) was administered via subcutaneous 
injection in the neck. Rimadyl (1 mg/kg; Pfizer) was injected to 
relieve pain. Baytril (10 mg/kg; Orion, Germany) was injected 
intraperitoneally once a day to prevent middle ear infections.
Histology analysis
The rats were anesthetized using the procedure described above, 
and this was followed by fixation through cardiac perfusion with 
0.01 M PBS containing 0.6% (v/v) heparin (pH 7.4) and then 
4% paraformaldehyde (Merck, Espoo, Finland). The isolated 
cochleae were rinsed with water for 1 minute to remove any PMs 
that may have attached to the middle ear mucosa and the round 
window membrane (RWM), and fixative was added for 2 hours 
(for whole mount samples) or overnight (for cryosection samples). 
The methods for perfusion, sample preparation, and confocal 
microscopy after PM delivery have previously been reported.8
Immunostaining
The cryosections were incubated with 1:20 preimmunized 
goat serum at room temperature for 60 minutes and then 
incubated with one of the following primary antibodies 
at 4°C overnight: rabbit anti-neurofilament-200 (NF-200) 
  polyclonal antibody (1:400; Sigma-Aldrich, Helsinki, 
Finland), rabbit polyclonal antibody to S100 (1:400; Abcam, 
Cambridge, UK), or rabbit polyclonal antibody to peripherin 
(1:100; Millipore). After washing in PBS, the specimens 
were incubated with fluorescein isothiocyanate-labeled 
goat anti-rabbit IgG (1:400; Sigma-Aldrich, USA) at room 
temperature for 60 minutes, followed by incubation with 4,6-
diamidino-2-phenylindole (10 µg/ml) for 10   minutes. After 
washing with PBS, the slides were mounted in   Fluoromount™ 
aqueous mounting medium (Helsinki, Finland).
Fluorescence signal analysis
Colocalization of the Tet1-PMs, ScrTet1-PMs, and unlabelled 
PMs with NF-200 immunostaining in confocal micrographs 
was analyzed using ImageJ 1.42q software (National 
Institutes of Health, Bethesda, MD).
Results
Tet1-PMs delivered via transtympanic 
injection
All the investigated PMs (Tet1-PMs, ScrTet1-PMs, and 
unlabelled PMs) were detected on the RWM, spiral   ligament 
PCL
PEG
PEG-b-PCL block
copolymer chain
Peptide
Dil
AB
Aqueous core
Spiral lamina canal
RWM TSF
SGCs
Cochleostomy
Catheter tip Intact RWM delivery
Figure 1 Illustration of polymersome schema and administration approaches. (A) Shows PEg-b-PCL block copolymers self-assembled in an aqueous environment to form 
polymersomes (PMs). The poly-ε-caprolactone (PCL) units of the polymer form a hydrophobic membrane; the polyethylene glycol (PEg) units form a hydrophilic corona 
around the interior cavity of the PM. The polymer can be functionalized with a short peptide sequence such as TAT or Tet1 prior to formation. The peptide-functionalized 
polymer can be blended with unfunctionalized polymer and, upon formation, these peptides are present on the PM surface. (B) Shows the delivery location of the PMs via 
intact round window membrane (rWM) (topical rWM delivery and transtympanic injection) and cochleostomy.
Abbreviations: rWM, round window membrane; SgCs, spiral ganglion cells; TSF, tractus spiralis foraminosus.
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fibrocytes, mesothelial cells in the scala vestibuli and ST, and 
Reissner’s membrane. However, none were present in the CN.
Tet1-PMs delivered via cochleostomy
Distribution of PMs in the spiral ganglion  
and the cochlea nerve
All of the PMs (Tet1-PMs, ScrTet1-PMs, and unlabelled 
PMs) were detected in the cochlea nerve (CN) within the 
spiral lamina canal, within the modiolus, and in the spiral 
ganglion satellite cells in Rosenthal’s canal (Figure 2). Only 
the Tet1-PMs were detected in nerve fibers in the tractus spi-
ralis foraminosus region (Figure 2 and Figure 4A), which are 
multiple tiny osseous canals that allow the axons to pass from 
the Rosenthal canal to the cochlea nerve in the modiolus.
A fluorescence signal intensity gradient was visualized 
from the distal to the proximal parts of the peripheral processes 
of the SGCs (Figure 3A–C). Nevertheless, the distribution 
patterns of the PMs in the peripheral processes of the SGCs 
were different: the Tet1-PMs were evenly distributed in the 
nerve fibers, while the majority of ScrTet1-PMs appeared 
within the epineurium surrounding the nerve bundle 
(a few of the PMs were found in nerve fibers), and the 
unlabelled PMs were detected mainly within the epineurium 
with only sparse uptake in the nerve fibers of peripheral 
processes (Figure 2; Figure 3D–F).
The neural structures showing PM distribution were 
further identified by immunostaining using NF-200, S100, 
and peripherin. As can be seen, the Tet1-PMs were local-
ized within or adjacent to NF-200-positive nerve fibers of 
SGCs (Figure 4B and F). In contrast, the scrambled and the 
unlabelled PMs were remote from the NF-200-positive nerve 
fibers (Figure 4C and D). Co-localization with S100-positive 
structures that represent the spiral ganglion satellite cells 
occurred with all PM types (Figure 5C, F, and I). None of 
the PMs were observed in neuronal soma of the SGCs identi-
fied by NF-200 immunostaining (Figure 5B, E, and H) and 
peripherin immunostaining (not shown).
Distribution of PMs in rWM, cochlea scala,  
and spiral ligament
All the PMs (Tet1-PMs, ScrTet1-PMs, and unlabelled PMs) 
were observed in the RWM, the mesothelial cells of the ST, 
and SV (Figure 2; Figure 3A–C), and the anterior and posterior 
spiral modiolar vein in the modiolus. In the scala media, PMs 
occasionally appeared in the inner and outer pillar cells of 
Corti’s organ. In addition, the scrambled and the unlabelled 
PMs were occasionally found in Hensen cells and Claudius 
cells (Figure 2; Figure 3B and C), while the Tet1-PMs were 
not detected in these cells. Tet1-PMs and ScrTet1-PMs 
were detected in the entire spiral ligament. Unlabelled PMs 
were only detected in the type IV and V spiral ligament 
fibrocyte districts of the SL (Figure 2; Figure 6).9,10 In contrast, 
all the PMs were occasionally found in the strial vascularis.
Discussion
Targeted axonal distribution of Tet1-PMs
Limited distribution of Tet1-PMs in cochlea after 
transtympanic injection
The Tet1-PMs administered via transtympanic injection 
showed no difference in distribution pattern in the cochlea 
compared to ScrTet1-PMs and unlabelled PMs, and no 
  targeting to the SGCs and CN was observed. However, PMs 
were observed in spiral ligament fibrocytes that lack GT1b 
receptors, indicating non-specific uptake.   Furthermore, no 
PMs were detected in the SGCs, a phenomenon that might 
be due to limited passage of the PMs through the RWM to the 
perilymph (Figure 2). The RWM is the major barrier between 
the middle ear and the cochlea, and consists in rats of three 
catheter
tip
Tet1-PMs
ScrTet1-PMs
Unlabelled PMs
RWM
Spiral lamina canal
SL
SGCs
TSF
CN
Figure 2 Illustration of the distribution of the polymersomes (PMs) after delivery 
using cochleostomy. In the cochlear nerve within the spiral lamina canal, the cochlear 
nerve in the tractus spiralis foraminosus region, and the spiral ligament (SL), the 
distribution patterns of Tet1-PMs, ScrTet1-PMs, and unlabelled PMs were different.
Notes: Arrowheads, the openings in ST that allowed the PMs to pass through.19 White 
arrows with dashed lines, the possible routes of PM distribution in the inner ear.
Abbreviations: Tet1-PMs, Tet1-functionalized PMs; ScrTet1-PMs, scrambled Tet1 
peptide modified PMs; RWM, round window membrane; SGCs, spiral ganglion cells; 
CN, cochlear nerve.
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Figure 3 Distribution of Tet1-PMs, ScrTet1-PMs, and unlabelled polymersomes (PMs) in rat cochlea after administration via cochleostomy. All three types of PM were 
detected in the mesothelial cells of ST and SV (arrows), and spiral ganglion (Sg) region (A–C). The fluorescence signal intensities of Tet1-PMs and ScrTet1-PMs were higher 
in the distal part (point 1 in A and B) than that in the proximal part (point 2 in A and B) of periphery processes of the spiral ganglion cells. Larger amount of ScrTet1-
PMs and unlabelled PMs were detected in the epineurium (arrows and dashed lines in E and F) of peripheral processes than within the peripheral processes, whereas the 
Tet1-PMs were evenly distributed within the peripheral processes (D). D and E are longitudinal sections of peripheral processes. F is a transverse section of a peripheral 
processe.
Notes: red: PMs. Blue: 4,6-diamidino-2-phenylindole. gray (D–F): bright field channel. Scale bar in panels (A–C) = 10 µm. Scale bar in panels (D–F) = 100 µm.
Abbreviations: SV, scala vestibuli; ST, scala tympani; Tet1-PMs, Tet1-functionalized PMs; ScrTet1-PMs, scrambled Tet1 peptide modified PMs.
A B CD
H G F E
SGCs
SGCs
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CN
Tet1/ScrTet1-PMs Unlabelled PMs Tet1-PMs ScrTet1-PMs
Figure 4 Location of Tet1-PMs, ScrTet1-PMs, and unlabelled polymersomes (PMs) in the cochlear nerve after administration via cochleostomy. Tet1-PMs (A) and ScrTet1-
PMs (E) were detected in the spiral ganglion (SG) and the nerve fibers in the tractus spiralis foraminosus region of the CN. Only Tet1-PMs were detected in the tractus 
spiralis foraminosus region (arrows in A). Panels B–D show the co-localization of the PMs with NF-200 (arrows in panel B). The co-localized points are indicated by black 
dots in panels F (arrows), G and H (analyzed by ImageJ software). Arrowheads in panel B pointed to SgCs.
Notes: red: PMs. Green: NF-200 immunostaining. Blue: 4,6-diamidino-2-phenylindole. Gray: bright field. Scale bar in A and E = 25 µm; scale bar in B–D = 10 µm.
Abbreviations: CN, cochlear nerve; NF-200, neurofilament 200; Tet1-PMs, Tet1-functionalized PMs; ScrTet1-PMs, scrambled Tet1 peptide modified PMs.
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layers: an outer epithelial layer that has tight junctions on the 
middle ear side and a continuous basement membrane beneath, 
a connective tissue core, and an inner endothelial layer.11 
Permeability of the RWM is poor, and only 0.01%–0.0001% 
of the original concentration of proteins applied on the 
RWM was detected in the inner ear perilymph.12,13 This 
is supported by our observation that PMs were present in 
the SGCs when administrated via cochleostomy, in which 
PMs are directly administered to the perilymph, avoiding   
the RWM.
Neurofilament targeting of the Tet1-PMs 
after intracochlear administration
After delivery via cochleostomy, Tet1-PMs demonstrated 
axonal targeting, as identified by the localization of   Tet1-PMs 
within or adjacent to neurofilaments, and their migration to the 
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Figure 5 Distribution of Tet1-PMs, ScrTet1-PMs, and unlabelled polymersomes (PMs) in the spiral ganglion architectures after administration via cochleostomy. All three types of 
PM administrated by cochleostomy were located in the spiral ganglion satellite cells (SgSCs, arrows). PMs were not detected in the neuronal soma of the spiral ganglion cells.
Notes: *Nucleus of type I spiral ganglion cells. red: PMs. green: NF-200 or S100 immunostaining. Blue: 4,6-diamidino-2-phenylindole. Scale bar = 10 µm.
Abbreviations: Tet1-PMs, Tet1-functionalized PMs; ScrTet1-PMs, scrambled Tet1 peptide modified PMs.
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Figure 6 Distribution of polymersomes with and without Tet1 functionalization in the spiral ligament after administration via cochleostomy. A shows the Tet1-PMs detected 
in type II, III, and IV spiral ligament (SL) fibrocyte district. B shows the ScrTet1-PMs detected in type I, II, III, and IV spiral ligament fibrocyte district. C shows the unlabelled 
PMs in type III spiral ligament fibrocyte district.
Notes: red: PMs. Blue: 4,6-diamidino-2-phenylindole. Scale bar = 50 µm.
Abbreviations: Tet1-PMs, Tet1-functionalized PMs; ScrTet1-PMs, scrambled Tet1 peptide modified PMs.
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tractus spiralis foraminosus region. Tet1 peptide is reported to 
bind to the GT1b receptor, which exists abundantly in neuronal 
membranes in the central nervous system14 and peripheral 
nerve axolemma.15 All the PMs (whether with or without the 
Tet1 peptide) were observed in spiral ganglion satellite cells of 
the spiral ganglion and the CN in the modiolus, as identified 
by S100 immunostaining, but only the Tet1-PMs were detected 
in nerve fibers identified by NF-200 immunostaining.
Neurons have active axonal transport machinery that moves 
substances from their distal terminals to the neuronal soma.16 
We hypothesized that the distribution of Tet1-PMs in the tractus 
spiralis foraminosus region (Figure 4A) was a consequence 
of active axonal transport from the CN in the modiolus to 
the neural soma of SGCs. However, the Tet1-PMs were not 
observed in the neuronal soma. This may be because the SGCs 
are enclosed by spiral ganglion satellite cells and there is no 
communication between these cells – the Tet1-PMs were 
located in distal axon compartments of SGCs that have little 
or no communication with the cell body compartment.17,18 In 
addition, gene expression in the lateral ventricle was reported 
after administration of Tet1-PEG-b-polyethylenimine contain-
ing plasmid DNA.6 This indicated that the PMs might release 
their cargos in the distal axon compartment, which could then 
penetrate separately into the cell body compartment of the 
neuron. Thus, Tet1-PMs could target the neurofilament of the 
CN; however, whether they effectively release their cargo into 
the cytoplasm needs further investigation.
Affinity of PMs to spiral ganglion satellite 
cells and spiral ligament fibrocytes
The Tet1-PMs,  ScrTet1-PMs,  and  unlabelled  PMs 
  administrated via cochleostomy were detected in spiral 
ganglion satellite cells. This suggested nonspecific affinity 
between these PMs and the spiral ganglion satellite cells. 
This is in line with previous in vitro studies with cochlear 
explants2 and spiral ganglion mixed cultures.1
We suggest that the reason more Tet1-PMs and ScrTet1-
PMs than unlabelled PMs were detected in the SL may be 
because the surface modification of PMs using the Tet1 and 
ScrTet1 peptides changes their affinity with spiral ligament 
fibrocytes. The PMs observed in spiral ligament fibrocytes 
were there due to non-specific uptake because the spiral 
ligament fibrocytes lack GT1b receptors.
Potential routes of PM distribution  
in the inner ear
After entry into the perilymph within the scala tympani, 
the PMs may migrate to the modiolus via openings in the 
modiolar wall of the ST and SV . They could then enter 
the peripheral processes of SGCs, either through open-
ings in the modiolar wall near the osseous spiral lamina or 
through the “tunnel fibers” in the Corti’s organ, and follow 
the CN from its distal to proximal part.19,20 This proposal 
is supported by the observation that the PM signal in the 
peripheral processes of the SGCs appears as a gradient 
(Figure 3). The PMs could then distribute in the lateral 
wall through the mesothelial sheet of the SL facing the 
ST (  Figure 2).19,20 Thereafter, PMs may migrate within the 
modiolus and lateral wall and reach the higher turns of 
the cochlea.21 PMs from the lateral wall were detected in 
the Hensen cells and Claudius cells so may also contribute 
to the distribution seen in the Corti’s organ. This result was 
comparable to the intracochlear distribution of lipid core 
nanocapsules, which are PMs of a similar size.20
Conclusion
The Tet1-PMs targeted axons of the SGCs after intraco-
chlear administration, and it was suggested that the Tet1-
PMs targeted axons through GT1b receptors. However, 
the Tet1-PMs were not detected in the neuronal soma of 
the SGCs. Tet1-PMs, ScrTet1-PMs, and unlabelled PMs 
were detected non-specifically in SGSCs and SL. The 
specific targeting of Tet1-PMs to axons could allow them 
to be used for drug delivery to the peripheral and central 
nervous systems in the treatment of hearing loss and other 
neurological diseases.
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